Fractional CIPO for Established Companies
You have a patent portfolio. It should be working.
You have issued patents, pending applications, and maintenance fees coming due. But is the portfolio generating licensing revenue? Protecting your product lines? Clearing the path for new ones? Giving you leverage in negotiations?
You already know the portfolio should be aligned to business goals. The question is how. Outside counsel files and prosecutes. They see their cases, not your portfolio, and not your business strategy. That is not just a conflict of interest; it is a structural incentive.
A fractional Chief IP Officer brings the structure, framework, and data to turn the portfolio from a cost line into a business function.
What Changes When This Role Exists
Decisions become structured and defensible
Every patent gets evaluated against the current business strategy. Licensing targets, maintenance decisions, and filing priorities all have a documented rationale. Leadership can answer hard questions about the IP position with confidence.
The portfolio starts generating revenue
Your patents may cover products your competitors are already selling. Microsoft, Nokia, Ericsson, and Qualcomm generate billions in licensing revenue. I identify targets, map claims to their products, and provide a balanced assessment of the position and the options: cross-licensing, marketplace enforcement, partnership leverage, licensing, or sale with a license-back. The CEO needs a guide with a balanced view, not a litigator with a billing incentive.
Technology space gets cleared before new products launch
I map the patent landscape around a new product before launch, not after. Two outputs: which third-party patents create risk and how to avoid them, and where the gaps in competitors’ positions are and how to fill them with blocking patents.
Maintenance decisions become capital allocation decisions
The default is to pay every fee on every patent, every time. The people sending the reminders get paid when you pay. I evaluate each patent at every maintenance window. Does it still protect revenue? Would you enforce it? Does it have enough life left? Dead patents get pruned. The savings go to patents that serve the current business.
The portfolio works in negotiations
Patents are trading cards. Cross-licenses, joint ventures, supplier agreements, standards bodies, and acquisition discussions all depend on what you bring to the table. I make sure your team knows what you hold and how to use it.
During COVID, patent abandonment rates nearly doubled. Not because companies made strategic decisions. Because the crisis gave them permission to stop paying for patents they should have abandoned years ago.
Strategic abandonment when times are good is discipline. Panic abandonment when times are bad is damage.
The Mistakes We See
These patterns destroy portfolio value at established companies. They happen when portfolio decisions are driven by inertia instead of structured review.
Maintenance fees on autopilot
The docketing system sends a reminder. Someone approves the payment. The cycle continues. Each payment should be a capital allocation decision. Instead, it is a rubber-stamped invoice.
Maintaining patents for the business you had, not the business you have
Products evolve. Markets shift. Competitors pivot. Features that justified a patent three years ago may be irrelevant today. The periodic review does not happen on its own. These are not difficult questions. They are uncomfortable ones.
Sunk cost psychology
You already spent significant money on this patent. Letting it die feels like admitting failure. But the money is spent. The only question is whether more money will produce future value. If the company has pivoted, the answer is no. Let the patent go.
Patents on life support
Some companies have been pouring money into their portfolio for 10 or 15 years without a return. Some patents issue with three years of enforcement left. Because the company disclosed too much in the original application, they are forced to do continuation applications year after year. Not for protection. For life support.
Competitors infringing and no one watching
Your patents may cover products competitors are already selling. Who is watching? Your counsel is waiting for you to call. That is business intelligence, not legal work.
No plan for what to do when someone infringes
You suspect a competitor is using your technology. You may be certain. But you have not done a claims analysis. You have not assessed damages. Your attorney’s instinct is to litigate, which is an endless source of revenue for them and a bottomless pit of expense for you. Enforcement does not have to mean litigation. It can mean a marketplace takedown, a tradeshow enforcement action, a cross-license, silent cross-licensing, leverage in a partnership or distribution agreement, or positioning for acquisition or IP-backed lending. The missing piece is a balanced assessment and a guide who is not incentivized to litigate.
Panic pruning instead of strategic pruning
During COVID, patent abandonment rates nearly doubled. Companies cut budgets across the board. The revealing part: they had been paying maintenance on patents they should have abandoned years ago. The crisis gave permission to do what discipline should have required all along.
Not filing improvement patents on your own technology
Your engineers solve new problems every quarter. If you do not file improvement patents, someone else will. A partner who gets under the hood during a collaboration. A competitor who reverse-engineers your product. A supplier who sees your technical direction. The original patents expire. The improvement patents filed by someone else are enforceable for twenty more years.
The Engagement
I start with the business. Products, revenue, customers, competitors, licensing history, partnership landscape. Every active patent gets evaluated against the current business strategy. After 90 days: a clear view of which assets carry weight, where licensing and standards opportunities exist, and how the portfolio should be managed going forward.
Phase 2 is a standing executive function. Competitive monitoring. Licensing and deployment guidance. Prosecution oversight. Outside counsel management. Maintenance decisions tied to strategy. Quarterly portfolio reviews.
Engagements are structured to portfolio scope and deployment objectives.
Common Questions
We have never done outbound licensing. Where do we start?
Portfolio-to-market mapping. Which patents cover products competitors are already selling? How strong are the claims? I provide a balanced assessment of the position and the full range of options: cross-licensing, marketplace enforcement, partnership leverage, licensing, or sale with a license-back.
How do we know which patents to keep and which to let go?
Three tests at every maintenance window. Does it still protect revenue? Would you enforce it? Does it have enough life left? Patents that fail get pruned.
How does FTO work for new products still in R&D?
I map the patent landscape before you commit to a design. Which third-party patents create risk? Where can you file blocking patents to clear the space? The product launches with FTO risks understood.
Can our patents qualify for standards bodies or patent pools?
If your patents cover solutions essential to implementing an industry standard, they may qualify. I evaluate candidates and manage the submission and FRAND licensing process.
How does this work with my existing patent attorney?
They keep drafting and prosecuting, but with clear direction and fast decisions. It becomes a working partnership.
